KDx Diagnostics
Business Services · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
2605 S Winchester Blvd, Campbell, Califo...Phone Number
(408) 628-7715Website
www.kdxdiagnostics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About KDx Diagnostics
Founded in 2017, KDx is focused on developing non-invasive cancer tests to improve early detection and therapy decisions in cancer. The URO17® bladder cancer test developed by KDx may prove to be the most sensitive and specific for bladder cancer developed to date. KDx plans to develop tests based on the same biomarker for other platforms and sample types and expand its product line into other cancer diagnostic tests. URO17® is available as LDT in the U.S.Explore more
KDx Diagnostics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is KDx Diagnostics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if KDx Diagnostics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once KDx Diagnostics has new funding data
Congratulate Masked Content for being promoted to Masked Content at KDx Diagnostics
KDx Diagnostics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Check if KDx Diagnostics has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on KDx Diagnostics recently announced quarterly report
Check out if KDx Diagnostics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when KDx Diagnostics launches new products
Recommended Actions
Find VP level buyers at KDx Diagnostics
Find 2 more new buyers
Compare Similar Companies to KDx Diagnostics
Compare insights from companies similar to KDx Diagnostics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
KDx Diagnostics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
KDx Diagnostics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about KDx Diagnostics.
KDx Diagnostics Tech Stack
A closer look at the technologies used by KDx Diagnostics
KDx Diagnostics News & Media
KDx Diagnostics Inc. announces new distribution partnerships in Europe for the URO17® NON-INVASIVE Urine Test for Bladder Cancer
LOS GATOS, Calif., Nov. 9, 2023 /PRNewswire/ -- KDx Diagnostics, a pioneering medical device company known for its innovative noninvasive urine test for bladder cancer, the URO17Ò test, is thrilled to announce strategic partnerships with leading distributors in Europe. These partnerships...KDx Diagnostics Inc. announces issuance of patents covering URO17® NON-INVASIVE Urine Test for Bladder Cancer in the United States and Europe
SAN JOSE, Calif., Oct. 5, 2023 /PRNewswire/ -- KDx Diagnostics Inc., a leading innovator in non-invasive bladder cancer tests, is pleased to announce the issuance of important patents in the US, EU, and South Korea relating to their joint work in developing new tests to aid in the...EmeritusDX and KDx Diagnostics Inc. Announce a Partnership to Offer the URO17 NON-INVASIVE Urine Test for Bladder Cancer
The Partnership Will Leverage the National Laboratory Network of EmeritusDX to Offer URO17 to Urologists Across the Country (PRWeb November 07, 2022) Read the full story at https://www.prweb.com/releases/2022/11/prweb19003841.htmKDx Diagnostics Inc. and UroGPO Announce a Partnership to Offer the URO17® NON-INVASIVE Urine Test for Bladder Cancer in the United States
SAN JOSE, Calif. and CLEVELAND, May 27, 2022 /PRNewswire/ -- KDx Diagnostics and UroGPO announced today the partnership to provide the URO17® test (Research Use Only in the US) for the detection of bladder cancer. URO17® is a non-invasive urine test with high sensitivity and negative...
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding KDx Diagnostics
Sign Up For FreeTo access detailed company insights
Founded in 2017, KDx is focused on developing non-invasive cancer tests to improve early detection and therapy decisions in cancer. The URO17® bladder cancer test developed by KDx may prove to be the most sensitive and specific for bladder cancer developed to date. KDx plans to develop tests based on the same biomarker for other platforms and sampl... Read More
